Heparin-induced thrombocytopenia pathophysiology
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia pathophysiology |
|
Heparin-induced thrombocytopenia pathophysiology in the news |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of platelet and endothelium.
Pathophysiology
- It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4).
- More than 90% patients have these anti–PF4-heparin antibodies in their plasma.
- These antibodies bind to the platelet's surface and induce their activation by cross-linking Fc IIA receptors and bind to the surface of the endothelium, inducing procoagulant activity.
- Platelets activated with these antibodies, increase their release of platelet factor 4 (PF4). Thus, a viscous cycle continues.